NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary has been awarded a project to support a preclinical program for a U.S. based biotech company. The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1001 USD | +28.83% | -43.06% | -77.27% |
05-14 | Top Midday Decliners | MT |
05-01 | Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-77.27% | 3.61M | |
+10.23% | 9.11B | |
-10.76% | 5.21B | |
+53.60% | 4.83B | |
+7.56% | 4.09B | |
-21.42% | 2.35B | |
+14.68% | 2.32B | |
+25.03% | 2.27B | |
-30.36% | 2.19B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SCPX Stock
- News Scorpius Holdings, Inc.
- Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client